Genetic testing hopes to speed up drug development in rare eye diseases
When it comes to fighting rare diseases, the biggest barrier to overcome is often the lack of knowledge around the condition. A free genetic test is hoping to combat this and speed up drug development in inherited retinal diseases.
Motus GI moving headquarters from Florida to Massachusetts
Motus GI is moving its corporate headquarters from Fort Lauderdale, Fla., to the greater Boston area in the second quarter of this year to support commercial efforts for its Pure-Vu colon cleansing system. The new headquarters will be in Norwood, Mass., closer to major medical device hubs, giving the company access to a bigger talent pool. Norwood is about 25 miles south of Boston.
AI and antibodies align
Last month, OSE Immunotherapeutics SA reported a new collaboration agreement with MAbSilico, which is based in Tours, France. The companies plan to use artificial intelligence (AI)-based solutions for therapeutic antibody drug development.
Cue up a potential answer to fighting tumors
In a “groundbreaking” preclinical study using the healing power of the body’s own immune system to treat human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), biopharmaceutical Cue Biopharma Inc. says it has demonstrated the ability of its lead biologic candidate, CUE-101, to activate tumor antigen specific antitumor immunity right on target.
Diasome Pharmaceuticals: A Future Without Lows?
Recently, Diasome Pharmaceuticals announced positive results from its Phase 2 OPTI-1 study on the efficacy of its hepatocyte directed vesicle (HDV) technology for preventing low blood sugar in patients with type 1 diabetes. The study results showed that this liver-targeted insulin may allow patients to reduce the amount of time they spend in hypoglycemia by using HDV technology and optimizing their relative basal and mealtime insulin doses.
Yeast of burden: how to develop better antifungal drugs
Long-lasting treatments for invasive fungal disease are becoming ever more necessary but there are many challenges to overcome in drug development. Natalie Healey talks to Cidara Therapeutics about finding safe and effective medicines in this space.
New IVIG Therapies to Treat Primary Immune Deficiencies with David Johnson GigaGen
David Johnson, CEO and co-founder, GigaGen discusses the company’s recombinant intravenous immunoglobulin (IVIG) therapy in development to treat patients with primary immune deficiencies and its potential to overcome limitations of current IVIG plasma-based therapies. David describes how GigaGen’s recombinant IVIG is not tied to plasma supplies and has the potential to provide a high purity, consistent and ultimately safer treatment alternative for patients in need.
Cerevance raising $60m for brain disease drug discovery
In the world of Longevity start-ups, it’s amazing how often we speak to founders who have a genuine interest in making a difference – often due to very personal experiences. Brad Margus, CEO of brain disease biopharma firm Cerevance, is a perfect example.
